APLS Q3 2021 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+774.6% YoY

Gross Profit

$6M97.4% margin

Operating Income

-$128M-2265.4% margin

Net Income

-$196M-3461.4% margin

EPS (Diluted)

$-2.28

QoQ Revenue Growth

+806.9%

Cash Flow

Operating Cash Flow

-$169M

Free Cash Flow

-$169M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$526M

Total Liabilities

$583M

Stockholders' Equity

-$57M

Cash & Equivalents

$284M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$646,000	+774.6%
Gross Profit	$6M	$646,000	+751.5%
Operating Income	-$128M	-$130M	+1.2%
Net Income	-$196M	-$136M	-44.1%

Revenue Segments

Product

$5M94%

Licensing And Other Revenue

$336,0006%